Restoring Balance From Hospital to Home: Updates on the Management of Acute and Chronic Hyperkalemia



On-demand CME/CE webcast previously recorded from the September 25, 2021, Hospital Medicine Summit


The risk of hyperkalemia increases significantly for patients with chronic kidney disease and for those who take common medications for heart failure, such as renin-angiotensin-aldosterone system inhibitors, which can increase potassium in the blood. Hyperkalemia may lead to cardiac arrest and death, with mortality being up to 30% in patients with severe hyperkalemia, if not treated rapidly.

Clinicians in a hospital and acute care setting would benefit from education on current epidemiologic and clinical trial data surrounding acute and chronic hyperkalemia so as to develop management strategies that address this electrolyte abnormality in ways that provide the most optimal outcome for affected individuals. This includes identifying those at risk for developing hyperkalemia, as well as employing evidenced-based therapies with supporting data shown to improve outcomes. Benefits of multidisciplinary transitional strategies will also be discussed. Application of the knowledge gained from this educational activity will help to improve patient outcomes.

Faculty Speaker

George L. Bakris, MD
Professor of Medicine
Director, AHA Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois


Release date: November 15, 2021
Expiration date: November 15, 2022
Estimated time to complete activity: 1 hour



This educational activity has been designed to meet the needs of physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists who practice in hospital, internal medicine, and chronic-care settings.


Upon completion of this educational activity, participants should be able to:

  • Discuss the importance of screening for, identifying, and assessing hyperkalemia
  • Describe current prescribing information for novel therapies to the effective management of acute and chronic hyperkalemia
  • Discuss recent safety and efficacy data supporting the use of novel therapies in patients with hyperkalemia
  • Review multidisciplinary strategies for achieving optimal outcomes from hospitalization through discharge and outpatient follow-up

There are no fees for participating and receiving CME/CE credit for this activity. During the period of November 15, 2021, through November 15, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%. Pharmacists must check the CPE monitor for their credits within 60 days of the activity.




Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Global Education Group designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number 0530-9999-21-287-H01-P.)

This is a knowledge-based activity.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or

For information about ACPE or ANCC accreditation of this activity, please contact Global at (303) 395-1782 or


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


Integrity Continuing Education, Inc. and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.


George L. Bakris, MD
Consulting Fees: Alnylam, Astra Zeneca, Bayer, Horizon, Ionis, KBP Biosciences, Merck, Novo Nordisk, Quantum Genomics, Vascular Dynamics

The following project managers/planners: Lindsay Borvansky, Ashley Cann, Donna Fausak, Andrea Funk, Liddy Knight, Kim Rodriguez, Rhys Williams, RN, MSN, FNP, Maria Rovere, MTSC, and Patima Tanapat, PhD, reported that they have no financial relationships or relationships to products or devices with ineligible companies related to the content of this CE activity.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


This CME activity is provided by Integrity Continuing Education, Inc..
This CEU/CNE activity is jointly provided by Global Education Group and Integrity Continuing Education, Inc..


This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.


Continue to Pretest